Gara Jalqabaatti › Kanisa Harkaa › Massachusetts › Boston
Qorannoo klinikaalii Kanisa Harkaa Boston, MA keessatti
Qorannoo 32 Kanisa Harkaa f Boston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Namoota walitti qabaa jira
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Namoota walitti qabaa jiraSadarkaa 3
- Dana Farber Cancer Institute, Boston
IKS014 in Advanced Solid Tumors That Express HER2
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Namoota walitti qabaa jiraSadarkaa 1/2
- Tufts Medical Center, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
Namoota walitti qabaa jira
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Mass General Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital Cancer Center, Boston
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Tufts Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Beth Israel Deaconess Medical Center, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- fi 2 dabalataa
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Dana-Farber Cancer Institute, Boston
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Namoota walitti qabaa jiraSadarkaa 2
- I-Mab Site 1002, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Mass General Hospital, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Namoota walitti qabaa jira
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Dana Farber Cancer Institute, Boston
Qorannoo Kanisa Harkaa magaalota biroo keessatti
- Houston, TXQorannoo 42
- New York City, NYQorannoo 31
- Nashville, TNQorannoo 28
- Baldwin Park, CAQorannoo 22
- Los Angeles, CAQorannoo 22
- Arlington, VAQorannoo 20
- Dallas, TXQorannoo 19
- San Antonio, TXQorannoo 19
- St. Louis, MOQorannoo 18
- Grand Rapids, MIQorannoo 18
- Washington, DCQorannoo 16
- Chicago, ILQorannoo 16
Qorannoo biroo Boston keessatti
- Saree OljooQorannoo 112
- Kansara Qara'a Non-Small CellQorannoo 90
- Saree (Gosoota Hunda)Qorannoo 85
- Kansara MetastatikiiQorannoo 63
- Kansarii ColorectalQorannoo 63
- Dhibee QaraQorannoo 62
- Kansarii OvariiQorannoo 61
- Kansarii ProstateQorannoo 59
- DepreshiniiQorannoo 52
- Kansa EndometiriyaaliiQorannoo 50
- Cufama OnneeQorannoo 44
- Leukemia Myeloidii HamaaQorannoo 44
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.